Ketamine therapy helps patients with major depressive disorder (MDD) and other mental health disorders. When administered in a safe, clinical setting at AwakeningsKC, ketamine stimulates nerve growth in the brain, allowing you to reflect internally in a tranquil, relaxing environment.
The best part? Ketamine has been proven to have antidepressant effects. Studies have shown that when used to treat depression, ketamine has a success rate of just over 80 percent.
AwakeningsKC offers ketamine in two forms: SPRAVATO® (esketamine) and intranasal ketamine.
Worried about shots? At AwakeningsKC, we use ketamine delivered via nasal spray. Painless and non-invasive, there are no needles required. Our clinic provides ketamine sprays in two forms:
SPRAVATO® (esketamine) is FDA-approved to treat major depressive disorder (MDD). Available in two precise doses, Spravato is covered by most insurance.
If your insurance doesn’t cover ketamine therapy, intranasal ketamine is your ideal choice. Featuring customized dosages, intranasal is an affordable version of ketamine therapy.

While both Spravato and intranasal ketamine are forms of ketamine, there are some subtle differences between the two.
Spravato: Spravato only contains one of the two molecules found in ketamine. However, this molecule binds more strongly to receptors in our brains involved in learning and memory. Spravato is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation.
Intranasal Ketamine: This form of ketamine contains both molecules found in ketamine. It’s not currently FDA-approved for treating any psychiatric conditions. However, it is far more affordable than Spravato if you don’t have insurance, and it has far wider dosing options than Spravato does.

At AwakeningsKC, we chiefly use ketamine therapy to treat depression. However, research has shown that ketamine therapy can treat other conditions as well, including:
If antidepressant medications are causing you to feel side effects, ketamine can be an effective alternative to SSRIs and more. Antidepressant side effects include:
And more. While ketamine can have side effects of its own, they’re usually mild as ketamine therapy uses very small dosages. Also, side effects from ketamine therapy generally go away four to 24 hours after each dose. It’s why we generally prohibit our patients from driving on the same day as their treatment.

Ketamine is the latest breakthrough in psychiatry in 50 years in treating depression. Unlike other antidepressants, ketamine has the potential to safely reduce the symptoms of depression and suicidality within hours of a single low dose.
Because of its rapidness and effectiveness, ketamine can improve symptoms even in patients with treatment-resistant depression and other mental health conditions.
You don’t need to struggle alone; reach out to AwakeningsKC today to learn more about our ketamine therapy program and how it can help you.
Ketamine is a medication that has been used since 1970 as an anesthetic and is a rapid-acting, extremely effective intervention to address treatment-resistant depression and suicidal ideation.

Ketamine works by modulating the glutamate system in the brain. It increases synaptic plasticity and connectivity, which are believed to play a key role in its rapid antidepressant effects.
At AwakeningsKC, we administer ketamine intranasally through a nasal spray device. The treatment is administered at our office under the supervision of a medical professional. The dosage and frequency vary based on patient needs and response to treatment.
When ketamine is administered intranasally, it can provide rapid relief within hours, unlike traditional medications, which can take weeks. Intranasal administration is also considered more convenient since patients do not have to receive an IV.
Spravato® (esketamine) is an FDA-approved medication containing a derivative of ketamine, which is covered by most insurances for the treatment of treatment-resistant depression and suicidal ideation.
Spravato® only comes in two fixed doses: 56 mg and 84 mg. Intranasal ketamine offers more individualized dosing and flexibility to treat other conditions like PTSD, anxiety, and chronic pain. Studies indicate ketamine might offer better overall response and remission rates for depression compared to esketamine, though both are effective treatments.
Choosing between ketamine and Spravato® depends on various factors, including individual patient needs, treatment history, and financial considerations. Consult with our team of professionals to determine the most suitable approach.
Ketamine treatments are offered on Mondays, Wednesdays, and Fridays at 10 AM, 12 PM, and 2 PM. Patients will do treatments 1-2x per week; the frequency will be determined by your treatment team.
Depending on your dosage, patients will complete 6-8 treatments. Once complete, you will meet with your provider to evaluate your progress and discuss the next steps.
Ketamine is not FDA-approved for mental health and is considered an “off-label” treatment.
We believe in making ketamine therapy available to anyone who needs it. Our admissions team will gladly discuss any and all payment options you have.
Patients are required to be at the office for a total of 2 hours from administration. During this time, our team will monitor your blood pressure and response to the medication.
Generally, ketamine is well-tolerated. Common side effects include nausea, dizziness, dissociation, and increased blood pressure.
Patients with the following may not be able to receive ketamine: uncontrolled blood pressure, active mania, active psychosis, schizophrenia, significant cardiac history, clinically significant substance abuse, current pregnancy, recent ocular surgery, intracranial pathology, and history of aneurysm, epilepsy or stroke.
The medication is sent to a local pharmacy, and the patient is responsible for picking it up or coordinating shipment to their home. The patient is responsible for bringing the medication to the clinic, where it will be stored for the duration of the treatment. The medication seal must be intact/untampered with for the patient to receive treatment.

Ketamine was first synthesized in 1962 by Calvin Stevens, an American scientist. The history of ketamine, for medical purposes, began as a replacement anesthetic for phencyclidine (PCP), which was needed because of its severe side effects.
In 1963, ketamine was patented in Belgium. Ketamine was first tested on humans in 1964, and it was noted that ketamine produced only minor hallucinogenic side effects by Dr. Edward Domino, a pioneering researcher at the University of Michigan.
Dr. Domino’s wife, Toni, later invented the phrase “dissociative anesthetic” for ketamine. The first report of human and animal use was in 1966.
The US Food and Drug Administration (FDA) approved ketamine for human use in 1970. It was mainly used on the battlefield when administered to soldiers during the Vietnam War who required surgical interventions or immediate pain control.
In the next three decades, ketamine was used as an anesthetic agent in operating rooms, emergency departments, or intensive care units.
Later in the 1990s, research on ketamine began to explore its potential as an antidepressant.